Return on Equity (ROE)
Updated 316h ago
Sector Performance
41th percentileEPAM
10.9%
Sector Median
13.8%
Sector Avg
31.4%
Deep Analysis
Return on Equity (ROE) measures how efficiently a company generates profit from every dollar of shareholder equity; EPAM's current ROE of 10.9% means it earns $0.109 for each $1 of equity.
This trails the sector median of 13.9%, placing EPAM in the 40th percentile among its peer group. The year-over-year change is not available, the quarter-over-quarter change is not available, and the trend direction for the last eight quarters is also not available, with only a single historical value of 10.9% reported. Because the level sits below the sector median and no trend data exist to indicate improvement or deterioration, the risk-opportunity profile is neutral — neither a clear warning nor a catalyst. This neutral stance aligns with the overall NEUTRAL verdict on the stock, as the metric confirms average relative performance without any directional signal to tilt the assessment.
Frequently Asked Questions
What does the Return on Equity (ROE) tell investors about EPAM?
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
How is the Return on Equity (ROE) calculated?
Return on Equity (ROE) is calculated as: Net Income / Shareholders' Equity.
Who are EPAM's closest peers by Return on Equity (ROE)?
The closest peers by Return on Equity (ROE) include: MRNA (-36.6%), FICO (-37.3%), XRAY (-37.7%), VRSN (-38.3%), MSCI (-45.3%).
The Formula
Net Income / Shareholders' Equity
Why It Matters
ROE measures how effectively management turns equity into profit. Consistently above 15% is typically considered strong. Negative equity distorts this metric.
Master EPAM's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full EPAM research report →EPAM
10.9%
Sector Median
13.8%
Sector Avg
31.4%
How EPAM's Return on Equity (ROE) compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.